The unique biology of a neoplasm is reflected by its distinct molecular profile compared with normal tissue. To better understand tumor development, we have undertaken a quantitative proteomic search for abnormally expressed proteins in colonic tumors from Apc Min/+ (Min) mice. By raising pairs of Min and wildtype mice on diets derived from natural abundance or 15 N-labled algae, we used metabolic labeling to compare protein levels in colonic tumor versus normal tissue. Because metabolic labeling allows internal control throughout sample preparation and analysis, technical error is minimized compared to in vitro labeling. Several proteins displayed altered expression, and a subset were validated via stable isotopic dilution using synthetic peptide standards. We also compared gene and protein expression among tumor and non-tumor tissue, revealing limited correlation. This divergence was especially pronounced for species showing biological change, highlighting the complementary perspectives transcriptomics and proteomics provide. Our work demonstrates the power of metabolic labeling combined with stable isotopic dilution as an integrated strategy for the identification and validation of differentially expressed proteins utilizing rodent models of human disease.
INTRODUCTION
Colon cancer is the third most prevalent cancer in the United States, causing nearly 100,000 diagnoses and 50,000 deaths in 2009 (1) . Though early stages are treatable, existing screening methods lack specificity or have poor patient compliance. Thus, many cases are undiagnosed until late stages when the prognosis is poor (2) . Given its prevalence, research is needed to uncover the molecular basis of colon cancer and reveal biochemical markers of disease.
To address this challenge, animal models have been developed, including several mouse strains (3) . The Apc Min/+ (Min) mouse carries a premature stop codon within the Adenomatous polyposis coli (Apc) gene, preventing normal expression (4, 5) . Min mice develop tumors in the colon and small intestine and are moribund within four months of birth. Loss of APC function in humans causes Familial Adenomatous Polyposis, a rare genetic form of colon cancer (6) . More generally, the APC gene is the most frequently mutated gene in a genome-wide survey of spontaneous human colonic tumors (7) . Thus the Min mouse is relevant for probing the biological basis of colon cancer. We have begun using quantitative proteomics to identify abnormally expressed proteins in colonic tumors from Min mice. Study of tumors should reveal proteins whose abnormal expression is a direct effect of tumorigenesis, rather than a secondary sign of ill health.
In a typical quantitative proteomics experiment, sample pairs are compared via isotopic labeling: one is labeled with multiple "light" isotopes, while the other is labeled with a matching tag containing "heavy" isotopes. Samples are then combined and analyzed, while the mass spectrometer distinguishes peptides from each based on mass. Usually isotopic tags are introduced in vitro via chemical (8, 9) or enzymatic (10) means. By contrast, an isotopic label may instead be introduced via growth on isotopically enriched food or media. This process, metabolic labeling, has often been used with bacteria, yeast (11) and cultured cells (12) , as well as plants (13, 14) . Less frequently, it has also been applied in mammals (15) (16) (17) . Though it can involve increased initial expense and effort, metabolic labeling is desirable because it allows differentially labeled samples to be combined at the outset of an experiment. The resulting internal control during sample preparation and analysis minimizes technical error compared to in vitro labeling techniques.
Here we describe use of metabolic labeling to compare protein expression in colonic tumors of Min mice versus normal epithelium from their wildtype counterparts. We subsequently verify abnormal expression of several proteins within colonic tumors via stable isotopic dilution (18) , demonstrating the power of untargeted proteomic profiling combined with targeted stable isotopic dilution for discovery and validation of disease-related proteins. We also compare proteomic and transcriptomic profiles and explore the complementary insight these strategies provide.
RESULTS

N Metabolic Labeling of Mice:
The key challenge in metabolic labeling is introducing an isotopic label via the medium or diet of the organism. Previously, Wu and MacCoss et al. demonstrated metabolic labeling of rats using a diet derived from 15 N-labeled Spirulina, supplemented with fats, vitamins, and a nitrogen-free carbohydrate base (15) . Spirulina is a protein-rich alga that can be purchased in >98%
15 N-labeled form. We adapted their protocol for use with mice.
We raised eight female mice, four Min and four wildtype, from weaning on the Spirulina-based diet. Each mouse was paired with a sister of the opposite genotype. One mouse in each pair was fed the 15 N-labeled diet, while the other was fed the natural abundance form. The isotopic label was switched between Min and wildtype mice from one pair to the next. This 'reciprocal labeling' scheme distinguishes relevant differences in protein expression from experimental artifacts (Figure 1 ).
At 68 days of age, mice were sacrificed and organs frozen in liquid nitrogen. Labeled and unlabeled tissues from each pair were combined, and protein samples were analyzed via LC-MS following extraction and tryptic digestion. Levels of 15 N enrichment were determined for peptides from each tissue by matching observed and theoretical isotopic distributions. Average 15 N enrichments are summarized in Table 1 .
We observed considerable variation in 15 N enrichment across tissues. As in rats, tissues with high protein turnover (e.g. intestinal tract) showed high levels of enrichment, while slower turnover tissues such as muscle and brain were lower. Enrichment differences across proteins within each sample were small (~ 1.0 %); comparable variation was seen among mouse pairs. All tissues were sufficiently enriched for quantitation, with corrections for incomplete incorporation.
Proteomic Comparison of Colonic Tumors and Normal Epithelium:
Colonic tumors from each Min mouse were combined with normal epithelium from its wildtype sister bearing the opposite isotopic label. Following protein extraction and digestion, samples were analyzed via LC-MALDI-Tof/Tof mass spectrometry. Peptides were identified via Mascot (19) and filtered to a 1% false discovery rate (FDR) via decoy database searching (20) . The protein-level FDR was below 1% for species identified and quantified in multiple replicates. Peptide and protein identities are summarized in Tables S1-S3.
Abundance ratios for 15 N-labeled and natural abundance forms of all peptides were determined via a novel algorithm (Supplementary Methods). Each protein's ratio was estimated by averaging the ratios of its constituent peptides within each replicate. Following normalization and log transformation, ratios for each protein were averaged across mouse pairs (Fig. S1 ). Proteins whose ratios differed from the normalized median by more than 2-fold and whose relative standard errors across replicates were less than 50% were considered differentially expressed (Table 2) [cf. Dong et al. (21) ]. Ten differentially expressed proteins were identified meeting these criteria; other differentially expressed proteins with greater biological variability were also seen (Table S4 ). Figure 2 summarizes quantitation of one protein, coronin, across all replicates, demonstrating its up-regulation in colonic tumors. Reciprocal labeling confirms that its differential expression reflects tissue type rather than labeling or analytic effects.
Validation of Selected Protein Observations via Stable Isotope Dilution:
While we identified several proteins with abnormal abundances, our survey includes a small biological sample. Furthermore, due to biological variability among the mouse pairs, we have chosen liberal criteria to identify differentially expressed proteins. Thus these preliminary observations must be validated in larger populations. While some observations are confirmed in the literature, we sought to confirm others experimentally. We selected three differentially expressed proteins -coronin, HMG-CoA synthase 2, and solute carrier family protein 25 (SCFP-25) -for validation via stable isotope dilution (SID) as proposed by Gerber et al. (18) Synthetic peptides were made to match unique tryptic peptides from each protein.
Heavy isotopes were added to each for use as internal standards for quantification. Labeled and unlabeled peptide forms were assayed via multiple reaction monitoring (Table S5 ). These peptides were spiked into tryptic digests from tumors and normal epithelia and used to quantify each protein (Fig. 3) .
Overall, SID results confirm differential expression of each protein, with additional replicates and greater precision from multiple reaction monitoring. These changes are statistically significant (p<0.05) at an FDR below 5% (22) . Compared to our initial survey, the observed abundance ratios were reduced in the SID experiments. This may arise from biological variability, or may reflect slightly different ages of mice used for validation.
These altered protein abundances could be specific to tumors, or they could be specific to the Min mutation and independent of the tumor phenotype. To distinguish these possibilities, we also used SID to quantify each protein in non-tumor tissue from the same Min mice. No significant difference in abundance relative to normal tissue from wildtype controls was observed for HMG CoA synthase or SCFP-25, relative to normal tissue from wildtype controls. In contrast, while we observed increased coronin expression in Min tumor tissue, we detected a slight but significant decrease in non-tumor tissue from Min colon relative to normal tissue (p=0.001). Thus the altered expression of these proteins is specific to tumor tissue.
Colonic Tumor Proteome versus Transcriptome:
To complement proteomic profiling, we compared gene expression in tumor versus normal epithelial tissue. While complete analysis of these data is beyond the scope of this report, here we compare protein and transcript expression for the 613 species identified in our proteomic survey (Table S6) .
RNA samples were extracted from four colonic tumor samples, fluorescently labeled, and mixed with a single labeled control RNA sample from wildtype colonic epithelia. Samples were analyzed via dual label microarray technology. Protein and RNA ratios were then aligned, and the combined dataset was filtered to include only molecules whose RNA and protein forms were quantified in multiple replicates.
Interestingly, only limited agreement is observed between protein and mRNA ratios for differentially expressed proteins (Table 3) . While four show similar changes at protein and mRNA levels, five change little at the mRNA level and one displays inverse protein and mRNA ratios. Three proteins whose protein and mRNA ratios are at odds were confirmed via SID, including HMG CoA Synthase, whose protein and mRNA ratios are reversed. More generally, when all proteins are considered, only a modest correlation between protein and mRNA ratios is observed (see Figure 4A ). This is consistent with other reports comparing protein and mRNA abundances (23) and comparing relative changes in protein and mRNA levels after biological perturbation (24) .
Clearly the quantitative relationship between mRNA and protein ratios is limited. However, requiring quantitative precision may be overly stringent, masking qualitative similarities that are biologically meaningful. Thus we classified protein and mRNA ratios as "Increased", "Decreased", or "Unchanged" and determined the frequency at which transcriptome and proteome analyses agreed (see Figure 4B and Table S7 ). Although the concordance is higher than correlation suggests, it is dominated by species that are unchanged between tumor and normal tissue. Those showing biological response vary, including cases with opposing protein and mRNA ratios. Overall, ~30% are classified differently at the protein and RNA levels, indicating that transcriptome and proteome data provide complementary views of a tumor's unique molecular profile.
DISCUSSION
A primary goal of our work has been identification of abnormally expressed proteins in colonic tumors from Min mice. Several such proteins have been revealed using 15 N metabolic labeling for proteomic comparison of colonic tumors versus normal epithelia. Three of these (coronin, HMG CoA synthase, and SCFP-25) have been confirmed via SID experiments. In addition, carboxylesterase 2 has been shown by others via Western blotting to be downregulated in human colonic tumors (25) . These results lend support to our approach.
We observed decreased transglutaminase 3 expression in tumors. This protein is normally expressed in mature epithelial cells. Its decreased protein and mRNA expression has previously been observed in oral and esophageal cancer (26, 27) .
Interestingly, we observed reduced non-gastric H+/K+ ATPase α in tumors. Though annotated as an H+/K+ ATPase, the rat form resembles a Na+/K+ ATPase (75% sequence identity) and possesses significant Na+/K+ activity (28, 29) . The mouse variant is also similar to mouse Na+/K+ ATPase (NP_659149; 65% sequence identity; Blast score (30): 1373; E-value<10 -100 ), suggesting it may transport sodium. This is significant because Na+/K+ ATPase activity is reduced in rat distal colon prior to tumor development (31) . Furthermore, this activity has localization and pharmacological properties that match those reported for this 'H+/K+ ATPase' with Na+/K+ activity (28, 7 29, 31) . Notably, the Na+/K+ ATPase α and β subunits suppress cell motility through activation of PI3 kinase and interaction with annexin II (32); thus decreased abundance could signal increasing cell motility.
Continuing this theme of increasing cell motility, our analysis revealed downregulation of α-actinin 2, and up-regulation of coronin and lymphocyte cytosolic protein 1 (also called L-plastin). α-Actinin interacts with E-cadherin, a structural protein within focal adhesions (33) whose expression is lost as epithelial cells assume mesenchymal properties in Min mice (34) . An associated drop in α-actinin has also been noted in tumors (35) . The protein L-plastin is also associated with focal adhesions, and its elevation induces proliferation, tissue invasion, and loss of E-cadherin in colorectal tumors (36) . In addition, because coronin inactivates the Actin-Related Protein (Arp) 2/3 complex, its increase promotes cell motility (37) . Expression of coronin 1C correlates with malignancy in glioma cells (38) . Furthermore, coronin increases in breast cancer cell lines (39) . Intriguingly, all these proteins play roles in cellular adhesion, and their observed changes imply increased cell motility that can signal transition of a tumor from relatively benign to invasive stages (34, 40) .
This trend toward increasing malignancy is noteworthy, as the tumors we studied are adenomas: tumors in this early stage are not yet capable of tissue invasion and metastasis. Other observations oppose cell motility. Rho-GTPases activate cytoskeletal rearrangement and have been implicated in a variety of cancers. We observed an increase in Rho-GDP dissociation inhibitor β, which inactivates Rho-GTPases, opposing cell motility (41) . Interestingly, activation of Rho-GTPases involves isoprenylation, and inhibition of this modification reduces cell motility and cancer progression. This inhibition has been achieved by blocking activity of HMG CoA reductase, an enzyme that provides precursors for this post-translational modification (41) . We observed decreased HMG CoA synthase, which immediately precedes HMG CoA reductase in this biosynthetic pathway. Though not previously implicated in tumor resistance, a decrease in HMG CoA synthase could reduce isoprenylation. Together, our proteomic observations capture the dynamic and conflicted nature of tissue in transition toward malignancy.
While our observations are generally consistent with the literature, the decreased expression of RNA-binding motif protein 3 (RBM-3) is novel. Previously, researchers identified RBM-3 as an oncogene whose expression in human colonic adenocarcinomas and colon-derived cell lines is elevated and increases as disease progresses (42) . Our observation of decreased RBM-3 expression in adenomas suggests that expression of this protein varies during tumor development, and that high levels of expression may be specific to advanced stages of disease.
Importantly, several preceding observations are novel for colonic tumors, and neither HMG CoA Synthase nor SCFP 25 have previously been implicated in tumor development. Differential expression of these proteins was confirmed via SID. Though further investigation will be required to understand the role, if any, of their diminished expression in early Min tumors, their discovery highlights the value of untargeted discovery approaches.
In principle, differences in protein expression could be effects of the Min mutation in normal tissue in addition to tumor tissue. This is important, as biochemical abnormalities have been reported in "normal" colonic tissue from humans lacking APC function (43) . However, we have observed that levels of coronin are decreased in nontumor colonic tissues of Min mice, in stark contrast to its increased levels in tumor tissue. Furthermore, we demonstrated via SID that our observations of the down-regulation of HMG CoA Synthase and SCFP 25 are specific to tumors. Additionally, many of the other changes we found were previously observed in tumors from independent disease models. Thus most of the differentially expressed proteins we observed are likely to be tumorspecific. Regardless, the differentially expressed proteins discovered by our strategy of differential mass spectrometry can be biologically significant, whether they arise in normal tissue heterozygous for the Min mutation or only in tumors.
While this study has yielded intriguing biological observations, it has importantly confirmed the utility of metabolic labeling for quantitative proteomics in mammals. Though metabolic labeling is often used in yeast, plants, bacteria, and cells in culture, its use in mammals has been relatively limited. Previously, metabolic labeling of rats for one and two generations was reported (15, 17) , as well as SILAC labeling of mice (16) . We have demonstrated sufficient levels of 15 N incorporation across many tissues and subsequently used metabolic labeling to identify differentially expressed proteins in colon tumors.
The reciprocal labeling design of our experiment has been important for ensuring high quality peptide quantitation and identification. Requiring inversion of 15 N: 14 N abundance ratios across replicates as isotopic labels are exchanged allows exclusion of quantification artifacts arising from inconsistent changes, coincidentally co-eluting species, and differences in diets (see Ref. (44)). Furthermore, exchanging isotopic labels minimizes bias due to different identification rates for labeled and unlabeled peptides, ensuring that all have comparable likelihood of identification. While the bias against identification of 15 N-labeled peptides is most pronounced with incomplete incorporation (45), subtle differences have been observed for peptides labeled to ~98% incorporation (13), especially as length increases (45) .
In addition to metabolic labeling, many in vitro labeling techniques are available, including chemical labeling approaches such as ICAT (8), ITRAQ (9) and acrylamide labeling (46) , and enzymatic approaches such as 18 O labeling (10) . For detailed comparisons of in vitro and in vivo labeling techniques see reviews by Beynon and Pratt (47) and Ong and Mann (48) . Since these methods introduce an isotopic label late during sample preparation, they are applicable to any protein sample. However, labeling via these techniques is sometimes incomplete: only peptides with certain functional groups are labeled (8) , or labeling reactions may be reversible (10) . Additionally, in vitro labeling techniques cannot control error introduced during early steps such as tissue homogenization and protein extraction prior to labeling and mixing of samples. In contrast, because metabolic labeling introduces an isotopic label into all proteins early, it provides internal control through all experimental steps. Metabolic labeling thus enables extensive fractionation of the mixed, differentially-labeled samples, particularly prior to tryptic digestion: techniques like subcellular fractionation, immunoprecipitation (49) , and SDS-PAGE may be used without increasing error. This internal control makes metabolic labeling a powerful tool to address the challenges of dynamic range.
Though metabolic labeling has been used in many multicellular organisms, it could be problematic in larger organisms or experiments imposing dietary constraints. Another approach for such circumstances is partial metabolic labeling (50, 51) . Rather than requiring nearly complete substitution of 15 N for 14 N, partial metabolic labeling employs 6% 15 N labeling. Through deconvolution of overlapping labeled and unlabeled peptide isotopic envelopes, ratios are derived with accuracy comparable to full metabolic labeling (51) . Much lower isotopic enrichment is required, extending the technique to organisms that cannot be efficiently or economically labeled to ~100% 15 
N.
While metabolic labeling and untargeted quantitative proteomics in general provide a valuable overview of protein expression, they are often not well suited to assessing biological variability. Achieving high proteome coverage usually requires significant fractionation; thus many LC-MS analyses are required for each biological sample. The associated time and expense restrict biological replicates, limiting characterization of biological variability. In contrast, though it requires prior selection of peptide targets, stable isotopic dilution is well-suited to rapid quantitative analysis of many samples to assess variability. These complementary techniques provide a powerful means of discovering broadly and then validating specifically differentially expressed proteins.
Our experimental design employed four biological replicates for discovery of differentially expressed proteins, minimizing technical variability while providing some indication of biological variability. This revealed three altered proteins whose expression was verified via stable isotopic dilution. Integration of these strategies was efficient: proteomic survey data aided selection of peptides from each target protein with favorable ionization, fragmentation, and chromatographic properties for use as internal standards. With technological advances allowing higher throughput peptide design (52-54), synthesis (55) and multiplexing to quantify dozens of peptides in a single run (56) , the use of stable isotopic dilution as a complement to untargeted proteomics surveys will surely increase.
Previous researchers have used microarrays to probe the transcriptome of intestinal tumors (57, 58) . Recently, Hung et al. used tumor transcriptome data to identify the provenance of plasma proteins whose abundance was directly associated with tumor development in Apc-mutant mice (59) . While transcriptome analyses provide insight, our data suggest that protein-level surveys provide an important complementary view. We found weak correlation between protein and mRNA ratios, in accord with previous published work (23, 24) . This reflects biological processes such as post-translational modification, protein degradation, and mRNA transcript processing, and is especially pronounced among species with altered abundance. Ultimately, both protein and mRNA expression profiles are required for comprehensive characterization of biological systems.
Overall, this study confirms the utility of metabolic labeling for proteomic characterization of mice, identifying abnormally expressed proteins in colonic tumors. Combined with stable isotope dilution for targeted validation, this provides a powerful integrated approach for identifying differentially expressed proteins. This protein-level view provides unique and valuable insight into biological systems, complementing gene expression profiling. Ultimately, this work can serve as the basis for future studies that will offer greater protein-level insight into this and other biological systems.
MATERIALS AND METHODS
An overview of experimental procedures is provided below. For complete details, see Supplementary Materials.
Quantitative proteomic analysis of mice via metabolic labeling: Four pairs of female Min and wild-type mice were raised from weaning on a diet derived from natural abundance or 15 N-labeled Spirulina. At sacrifice, natural abundance and 15 N-labeled samples were combined for protein extraction and digestion. Tissue digests were analyzed via nano-LC-ESI-QTOF mass spectrometry. Peptides were identified via Mascot and filtered to a 1% FDR via decoy database searching. 15 N enrichment levels were determined by fitting observed isotopic envelopes to predicted isotopic distributions. Colonic tumor samples were analyzed via LC-MALDI using a Tof/Tof mass spectrometer and peptides were quantified via a novel algorithm. The peptide FDR for the colonic tumor samples was 1% and the protein FDR was 5%, though this fell below 0.8% when the dataset was restricted to peptides observed in multiple replicates, as required for quantitative analysis.
Stable isotopic dilution experiments:
Colonic tumor and normal tissue samples were homogenized and proteins extracted. During tryptic digestion, synthetic isotopically labeled peptides whose sequences matched unique tryptic peptides within the target proteins were introduced as standards for quantitation. Samples were analyzed via multiple reaction monitoring on a Q-Trap mass spectrometer with HPLC separation.
Microarray analysis: RNA was extracted from four colonic tumors obtained from three female Min mice as well as normal epithelium from a single female wild-type mouse. RNA samples were labeled with fluorescent dyes and each tumor RNA sample was pooled with a portion of RNA from the single wild-type control. Samples were analyzed via dual labeling microarray techniques (60) . Array data have been deposited on the NIH GEO website.
Gary Case for synthesis of peptide standards, and to Takis Papoulias (U. of Michigan) for use of his software (T2DExtractor Each protein was quantified in multiple mouse pairs, with a mean ratio exceeding a twofold change and a relative standard error of less than 50% (c.f. (21)). Mean microarray expression ratios are also listed for each. Ratios are in Log 2 form and are expressed as the ratio of tumor to normal tissue.
Figure Legends
Figure 1: Reciprocal Labeling Scheme Four Min and four wild-type mice were raised on Spirulina-based food (top). Each was paired with a sibling bearing the opposite genotype. One mouse in each pair was raised on the 14 N diet, while the other was raised on the 15 N diet. The isotopic label was exchanged across genotypes from one mouse pair to the next, allowing genotypedependent differences to be distinguished from various artifacts due to the pattern of ratio inversions across the mouse pairs (bottom).
Figure 2: Consistent Differential Expression of Coronin
The protein coronin was shown via reciprocal isotopic labeling to be elevated in tumor tissue across all mouse pairs, regardless of isotopic label (panel A). The mean ratio (+/-S.E.) for each mouse pair is plotted in panel B, showing low variability within and across biological replicates.
Figure 3: Confirmation of Protein Expression via Stable Isotopic Dilution
Three differentially expressed proteins were quantified in tumor and non-tumor tissue from Min mice and normal tissue from wildtype controls via stable isotopic dilution using synthetic, isotopically-labeled peptide standards. Differential expression in tumor relative to wildtype tissue was confirmed for each and was significant (p < 0.05) via unpaired two-sample T-tests, assuming unequal variance. When non-tumor tissue from Min mice was compared with normal colonic tissue, no significant difference was observed for two proteins (HMG CoA Synthase and SCFP-25), while a small but significant decrease in coronin was observed (p=0.001). All cases of differential expression remain statistically significant at a 5% FDR. Error bars represent +/-1 standard error.
Figure 4: Protein versus mRNA Ratios
Mean ratios are plotted for each protein as a function of mean mRNA ratio, with the bestfit line determined by linear regression (panel A). Bootstrap analysis of Pearson product moment correlation coefficients among pairs of microarray and proteomics replicates suggests a correlation of only 0.33 (asymmetric 95% confidence interval: 0.05-0.37). The Spearman rank correlation coefficient was also 0.33. Dotted lines indicate two-fold changes in expression; these thresholds were used to classify protein and mRNA ratio measurements qualitatively as "up", "down", or "same" (panel B). The correlation between mRNA and protein ratios is limited, and most agreement is among those species showing no significant change at either protein or mRNA levels. 
